Literature DB >> 26914113

Evaluation of SCUBE-1 and sCD40L biomarkers in patients with hypothyroidism due to Hashimoto's thyroiditis: a single-blind, controlled clinical study.

B Bilir1, N Soysal-Atile, B Ekiz Bilir, I Yilmaz, I Bali, N Altintas, D Baykiz, M Aydin, S Guldiken.   

Abstract

OBJECTIVE: This study was performed to investigate the levels of platelet activation marker SCUBE-1 and sCD40L which plays some role in the progression of atherosclerosis, in patients with hypothyroidism due to Hashimoto's thyroiditis. PATIENTS AND METHODS: The cohort of this study includes 90 patients and 35 healthy volunteers, who admitted to the internal medicine out-patient. Simultaneously in the same samples; SCUBE-1 and sCD40L measurements were accomplished by enzyme-linked immunosorbent assay (ELISA). The data obtained were analyzed statistically.
RESULTS: Hypothyroidism due to Hashimoto's thyroiditis in comparison to the control group that includes healthy volunteers; SCUBE-1 and sCD40L, were increased. And these results were statistically significant (p < 0.05).
CONCLUSIONS: SCUBE-1 and sCD40L levels were increased in Hashimoto's hypothyroidism patients. This may indicate an increased endothelial dysfunction, platelet activation and cardiovascular risk in hypothyroidism. SCUBE-1 and sCD40L may be helpful in cardiovascular risk assessment of hypothyroid patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914113

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  A new biomarker for the early diagnosis of ovarian torsion: SCUBE-1.

Authors:  Hacer Uyanikoglu; Nese Gul Hilali; Mesut Yardimciel; Ismail Koyuncu
Journal:  Clin Exp Reprod Med       Date:  2018-06-29

2.  sCD40L Is Increased and Associated with the Risk of Gestational Diabetes Mellitus in Pregnant Women with Isolated TPOAb Positivity.

Authors:  Xinxin Chen; Qingyao Wang; Xiangguo Cong; Shuyi Jiang; Shuxiang Li; Qiong Shen; Lei Chen
Journal:  Int J Endocrinol       Date:  2022-08-13       Impact factor: 2.803

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.